Preferred Label : PSMA-1007;
Origin ID : C000624634;
UMLS CUI : C4546620;
ATC code(s)
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
https://www.has-sante.fr/jcms/p_3498747/fr/radelumin-18f-psma-1007-cancer-de-la-prostate
2024
false
false
false
France
radiopharmaceuticals
insurance, health, reimbursement
Positron-Emission tomography
neoplasm staging
Prostate-Specific antigen
PSMA-1007 (18F)
evaluation of the transparency committee
prostatic neoplasms
PSMA-1007
Fluorine-18
---
https://www.has-sante.fr/jcms/p_3368278/fr/radelumin-18f-psma-1007
2022
false
false
false
France
Fluorine F 18 PSMA-1007
insurance, health, reimbursement
prostatic neoplasms
neoplasm recurrence, local
PSMA-1007
Positron-Emission tomography
radiopharmaceuticals
fluorine radioisotopes
injections, intravenous
Biochemically Recurrent Prostate Carcinoma
PSMA-1007 (18F)
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3337433/fr/radelumin-18f-psma-1007-cancer-de-la-prostate
https://www.has-sante.fr/jcms/p_3337451/fr/decision-n-2022-0144/dc/sem-du-28-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-radelumin
2022
false
false
false
France
neoplasm recurrence, local
Positron-Emission tomography
insurance, health, reimbursement
radiopharmaceuticals
fluorine radioisotopes
PSMA-1007
injections, intravenous
Fluorine F 18 PSMA-1007
guidelines for drug use
Biochemically Recurrent Prostate Carcinoma
PSMA-1007 (18F)
evaluation of the transparency committee
prostatic neoplasms
---
https://www.has-sante.fr/jcms/p_3352203/fr/radelumin-18f-psma-1007-cancer-de-la-prostate
2022
false
false
false
France
French
evaluation of the transparency committee
PSMA-1007
Positron-Emission tomography
prostatic neoplasms
neoplasm recurrence, local
Fluorine-18
Prostate-Specific antigen
PSA Progression
PSMA-1007 (18F)
---
